X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (22124) 22124
Publication (3141) 3141
Book Review (336) 336
Book Chapter (142) 142
Book / eBook (139) 139
Conference Proceeding (46) 46
Reference (30) 30
Dissertation (17) 17
Newsletter (9) 9
Newspaper Article (3) 3
Magazine Article (2) 2
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (15313) 15313
male (10346) 10346
rats (8702) 8702
neurosciences (7799) 7799
index medicus (7763) 7763
pharmacology & pharmacy (6322) 6322
humans (5326) 5326
mice (4820) 4820
morphine (4077) 4077
rats, sprague-dawley (3594) 3594
dose-response relationship, drug (3401) 3401
female (3076) 3076
narcotic antagonists - pharmacology (2839) 2839
morphine - pharmacology (2759) 2759
naloxone - pharmacology (2394) 2394
opioid receptors (2306) 2306
analgesics, opioid - pharmacology (2255) 2255
pain (2249) 2249
receptors (2160) 2160
article (2069) 2069
analgesia (1964) 1964
brain (1952) 1952
rat (1931) 1931
biochemistry & molecular biology (1922) 1922
receptors, opioid, mu - metabolism (1899) 1899
rats, wistar (1847) 1847
naltrexone - pharmacology (1832) 1832
receptors, opioid - metabolism (1625) 1625
psychiatry (1623) 1623
opioids (1607) 1607
neurons (1554) 1554
naltrexone - analogs & derivatives (1526) 1526
receptors, opioid - drug effects (1484) 1484
receptors, opioid, mu - agonists (1441) 1441
analgesics - pharmacology (1385) 1385
in vitro techniques (1340) 1340
naloxone (1305) 1305
antinociception (1289) 1289
mu-opioid receptor (1286) 1286
brain - metabolism (1255) 1255
analysis (1242) 1242
ligands (1241) 1241
receptors, opioid, mu - antagonists & inhibitors (1238) 1238
dopamine (1211) 1211
rodents (1196) 1196
research (1193) 1193
receptor (1190) 1190
nucleus-accumbens (1134) 1134
activation (1112) 1112
receptors, opioid - physiology (1098) 1098
time factors (1098) 1098
disease models, animal (1088) 1088
opioid (1084) 1084
behavior, animal - drug effects (1072) 1072
narcotics (1072) 1072
rat-brain (1066) 1066
opioid receptor (1063) 1063
clinical neurology (1034) 1034
physiology (1015) 1015
expression (1014) 1014
neuropathic pain (1009) 1009
spinal-cord (1009) 1009
pharmacology (971) 971
neurology (960) 960
neurons - drug effects (942) 942
narcotics - pharmacology (941) 941
physiological aspects (925) 925
binding (918) 918
analgesics (917) 917
peptides (916) 916
enkephalins - pharmacology (914) 914
biomedicine (910) 910
rats, inbred strains (909) 909
behavioral sciences (906) 906
pain - drug therapy (899) 899
tolerance (898) 898
beta-endorphin (890) 890
mice, inbred c57bl (881) 881
nervous system (877) 877
adult (864) 864
anesthesiology (864) 864
injections, intraventricular (863) 863
cell biology (850) 850
care and treatment (830) 830
ventral tegmental area (828) 828
guinea pigs (827) 827
motor activity - drug effects (825) 825
drug interactions (823) 823
enkephalin, ala-mephe-gly (822) 822
receptors, opioid, mu - drug effects (821) 821
inhibition (815) 815
naltrexone (810) 810
brain - drug effects (805) 805
proteins (793) 793
chemistry, medicinal (787) 787
antagonist (785) 785
antagonists (783) 783
reward (779) 779
agonist (775) 775
endocrinology & metabolism (770) 770
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (99) 99
Online Resources - Online (7) 7
UofT at Mississauga - Stacks (5) 5
Collection Dvlpm't (Acquisitions) - Closed Orders (4) 4
UTL at Downsview - May be requested (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
UofT at Scarborough - Stacks (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Gerstein Science - Periodical Stacks (1) 1
Providence Healthcare - Reference (1) 1
Providence Healthcare - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (22217) 22217
Russian (62) 62
German (30) 30
Japanese (30) 30
Spanish (22) 22
French (21) 21
Chinese (16) 16
Polish (4) 4
Korean (3) 3
Arabic (1) 1
Czech (1) 1
Italian (1) 1
Norwegian (1) 1
Portuguese (1) 1
Romanian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 06/2018, Volume 2018, Issue 6, p. CD006332
Background Opioid-induced bowel dysfunction (OIBD) is characterised by constipation, incomplete evacuation, bloating, and gastric reflux. It is one of the... 
Piperidines [therapeutic use] | EFFICACY | SAFETY | Humans | GUIDELINES | Gastrointestinal Agents [therapeutic use] | Intestinal Diseases [chemically induced; drug therapy] | MEDICINE, GENERAL & INTERNAL | Receptors | SUBCUTANEOUS METHYLNALTREXONE | Constipation [chemically induced; drug therapy] | PARALLEL-GROUP | Nalbuphine [therapeutic use] | mu [antagonists & inhibitors] | Naloxone [therapeutic use] | INDUCED CONSTIPATION | Opioid-Related Disorders [drug therapy] | Naltrexone [analogs & derivatives; therapeutic use] | Opioid | Quaternary Ammonium Compounds [therapeutic use] | PROLONGED-RELEASE TABLETS | Defecation [drug effects] | PAIN | Narcotic Antagonists [therapeutic use] | DOUBLE-BLIND | ADVANCED ILLNESS | Naltrexone - analogs & derivatives | Naltrexone - therapeutic use | Opioid-Related Disorders - drug therapy | Intestinal Diseases - chemically induced | Male | Palliative Care | Neoplasms - complications | Nalbuphine - therapeutic use | Female | Constipation - drug therapy | Oxycodone - adverse effects | Oxycodone - therapeutic use | Defecation - drug effects | Quaternary Ammonium Compounds - therapeutic use | Intestinal Diseases - drug therapy | Narcotic Antagonists - adverse effects | Naloxone - therapeutic use | Receptors, Opioid, mu - antagonists & inhibitors | Constipation - chemically induced | Randomized Controlled Trials as Topic | Narcotic Antagonists - therapeutic use | Piperidines - therapeutic use | Naloxone - adverse effects | Gastrointestinal Agents - therapeutic use | Naltrexone - adverse effects
Journal Article
Neuropharmacology, ISSN 0028-3908, 03/2018, Volume 131, pp. 116 - 127
Journal Article
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, ISSN 0815-9319, 05/2019, Volume 34, Issue 5, pp. 818 - 829
Background and Aim Opioid-induced constipation (OIC) is a frequent adverse event (AE) that impairs patients' quality of life (QOL). Peripherally acting... 
PLACEBO | NONCANCER PAIN | NALOXEGOL | opioid-induced constipation | meta-analysis | CONTROLLED PHASE-3 TRIAL | RECEPTOR ANTAGONIST | peripherally acting mu-opioid antagonist | IMPACT | INDUCED BOWEL DYSFUNCTION | SUBCUTANEOUS METHYLNALTREXONE | DOUBLE-BLIND | ALVIMOPAN | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, ISSN 0190-9622, 10/2010, Volume 63, Issue 4, pp. 680 - 688
During the past two decades, systemic mu-opioid receptor antagonists (MORA) have been used in the treatment of various forms of chronic pruritus. In a number... 
pruritus | itch | OPIATE ANTAGONIST | INTRATHECAL MORPHINE | NALOXONE INFUSIONS | therapy | atopic dermatitis | CHRONIC CHOLESTASIS | INTRACTABLE PRURITUS | NALMEFENE THERAPY | DERMATOLOGY | opioid receptor antagonist | ATOPIC-DERMATITIS | DOUBLE-BLIND | UREMIC PRURITUS | sensory nerve fibers | ORAL NALTREXONE TREATMENT
Journal Article
Journal Article
Journal Article
Neuropharmacology, ISSN 0028-3908, 10/2012, Volume 63, Issue 5, pp. 905 - 915
Mu-opioid and CB1-cannabinoid agonists produce analgesia; however, adverse effects limit use of drugs in both classes. Additive or synergistic effects... 
Analgesia | Morphine | Marijuana | G-protein | Adenylyl cyclase | CB1 receptors | AGONIST MORPHINE | ACTIVATION | PROTEIN-KINASE | CB1 CANNABINOID RECEPTOR | SYNERGISTIC INTERACTIONS | NEUROSCIENCES | INHIBITION | KAPPA | FULL AGONIST | ADENYLYL-CYCLASE | PHARMACOLOGY & PHARMACY | RAT-BRAIN | Pyrazoles - therapeutic use | Receptor, Cannabinoid, CB2 - agonists | Humans | Analgesics, Opioid - pharmacology | Receptors, Opioid, mu - agonists | Piperidines - pharmacology | Cannabinoid Receptor Agonists - therapeutic use | Recombinant Proteins - antagonists & inhibitors | Piperidines - metabolism | Receptors, Opioid, mu - metabolism | Morpholines - metabolism | Analgesics, Non-Narcotic - metabolism | Drug Inverse Agonism | Mice | Analgesics, Opioid - metabolism | Kinetics | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | Analgesics, Opioid - antagonists & inhibitors | Cannabinoid Receptor Agonists - metabolism | Cricetulus | Analgesics, Non-Narcotic - pharmacology | Cannabinoid Receptor Agonists - pharmacology | Receptor, Cannabinoid, CB2 - genetics | Analgesics, Opioid - adverse effects | Narcotic Antagonists - metabolism | Receptor, Cannabinoid, CB1 - agonists | Analgesics, Non-Narcotic - adverse effects | Cannabinoid Receptor Agonists - adverse effects | Morpholines - adverse effects | CHO Cells | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Binding, Competitive | Recombinant Proteins - metabolism | Cricetinae | Morpholines - pharmacology | Narcotic Antagonists - adverse effects | Recombinant Proteins - agonists | Analgesics, Non-Narcotic - therapeutic use | Pyrazoles - metabolism | Mice, Inbred Strains | Receptors, Opioid, mu - antagonists & inhibitors | Receptor, Cannabinoid, CB1 - metabolism | Receptor, Cannabinoid, CB2 - metabolism | Animals | Narcotic Antagonists - therapeutic use | Piperidines - therapeutic use | Narcotic Antagonists - pharmacology | Piperidines - adverse effects | Receptors, Opioid, mu - genetics | Index Medicus | Drugs | Pain perception | Opioid receptors | Cyclic AMP | Opioid receptors (type mu) | Antagonists | Cannabinoid CB1 receptors | Guanine nucleotide-binding protein | Antagonism | Cell activation | Side effects | Inverse agonists | CB1 Receptors | Adenylyl Cyclase
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2019, Volume 380, Issue 6, pp. 601 - 602
To the Editor: Kwatra et al. (Oct. 18 issue) 1 report on a patient with pruritus related to anti–programmed death 1 (PD-1) antibodies who had a response to... 
MEDICINE, GENERAL & INTERNAL | Narcotic Antagonists | Receptors, Opioid, mu | Programmed Cell Death 1 Receptor | Pruritus | Humans | PD-1 protein | Narcotics | Opioid receptors (type mu) | Skin | Inflammation | Naltrexone | Patients
Journal Article
DRUG DEVELOPMENT RESEARCH, ISSN 0272-4391, 08/2018, Volume 79, Issue 5, pp. 234 - 238
Background: Samidorphan, a -opioid receptor antagonist, is in clinical development for central nervous system related diseases. The discriminative stimulus... 
CHEMISTRY, MEDICINAL | NALTREXONE | drug discrimination | opioid | PHARMACOLOGY & PHARMACY | rats | RECEPTORS | BLOCKADE | antagonist | morphine | PARADIGM | Drug abuse | Morphine
Journal Article
BRITISH JOURNAL OF PHARMACOLOGY, ISSN 0007-1188, 11/2012, Volume 167, Issue 5, pp. 1111 - 1125
BACKGROUND & PURPOSE Loperamide is a selective mu opioid receptor agonist acting locally in the gastrointestinal (GI) tract as an effective anti-diarrhoeal but... 
RAT | irritable bowel syndrome | DELTA | opioid | VISCERAL HYPERALGESIA | gastrointestinal secretion | KNOCKOUT MICE | ARRIVE GUIDELINES | MUSCLE-CELLS | INTESTINAL INFLAMMATION | visceral pain | IN-VIVO | motility | PHARMACOLOGY & PHARMACY | SYNDROME IBS | d opioid receptor | IRRITABLE-BOWEL-SYNDROME
Journal Article